<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01005888</url>
  </required_header>
  <id_info>
    <org_study_id>LEVP2005-1/Part B</org_study_id>
    <nct_id>NCT01005888</nct_id>
  </id_info>
  <brief_title>C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks</brief_title>
  <official_title>LEVP2005-1/Part B: A Double-blind, Placebo-Controlled, Clinical Study to Investigate the Efficacy and Safety of Purified C1 Esterase Inhibitor (Human) as Prophylactic Treatment to Prevent HAE Attacks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objective was to determine the safety and efficacy of C1INH-nf for the prevention
      of acute HAE attacks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects were given diary cards and instructed to document all HAE attacks on a daily basis.
      Subjects evaluated their symptoms over the previous 24 hours, noting the severity and
      duration of swelling at each of 5 locations (abdominal, genitourinary, facial, respiratory
      [including laryngeal], and/or extremity).

      The study design also allowed for administration of open-label C1INH-nf (1,000 U of C1INH-nf
      administered IV [repeated after 60 minutes, if necessary] for treatment of laryngeal
      angioedema or if deemed necessary by the investigator; 1,000 U of C1INH-nf administered IV
      [single dose] prior to emergency surgical procedures).

      A total of 26 subjects were enrolled in the study. One subject received open-label C1INH-nf
      but withdrew prior to randomization. Another subject was randomized but withdrew prior to
      receiving study drug. Twenty-four (24) subjects were randomized and treated with blinded
      study drug. In total, 25 subjects received at least 1 dose of study drug and were analyzed
      for safety; all 25 subjects were exposed to C1INH-nf and 23 subjects were exposed to placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Hereditary Angioedema (HAE) Attacks During Each Prophylactic Therapy Period</measure>
    <time_frame>12 weeks</time_frame>
    <description>An HAE attack was defined as the subject-reported indication of swelling at any location following a report of no swelling on the previous day. Analyses include observed attack counts and normalized attack counts (i.e., the number of attacks observed during each therapy period, normalized for the number of days the subject participated in that period).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subject Withdrawals During Each Prophylactic Therapy Period</measure>
    <time_frame>12 weeks</time_frame>
    <description>At the end of each therapy period, each subject was assigned a yes/no drop-out status. A drop-out was defined as a subject who did not have a Week 12 visit record.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Severity of HAE Attacks During Each Prophylactic Therapy Period</measure>
    <time_frame>12 weeks</time_frame>
    <description>All attacks in each therapy period were assigned a value of 1 (mild), 2 (moderate), or 3 (severe). Attack severity was considered the highest value assigned by the subject to any swelling location during the attack. Average severity was set to 0 if there was no attack in a period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Duration of HAE Attacks During Each Prophylactic Therapy Period</measure>
    <time_frame>12 weeks</time_frame>
    <description>The duration of an attack was measured from the first report of swelling at any one of the five locations (abdominal, genitourinary, facial, respiratory [including laryngeal], or extremity) until the first subsequent report of &quot;no swelling&quot; at all five locations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Open-label C1INH-nf Infusions Required During Each Prophylactic Therapy Period</measure>
    <time_frame>12 weeks</time_frame>
    <description>The study design allowed for subjects to be treated with open-label C1INH-nf for laryngeal angioedema, if deemed necessary by the investigator, or prior to emergency surgical procedures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antigenic C1 Inhibitor (C1INH) Serum Levels</measure>
    <time_frame>Pre-infusion to 1 hour post-infusion at Visit 1 and Weeks 4, 8, and 12</time_frame>
    <description>Change in antigenic C1INH serum levels from pre-infusion to 1 hour post-infusion at Visit 1 and Weeks 4, 8, and 12. Pre-infusion samples obtained at Visit 1 of each therapy period (i.e., baseline) were used to determine change at 1 hour post-infusion for all visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional C1INH Serum Levels</measure>
    <time_frame>Pre-infusion to 1 hour post-infusion at Visit 1 and Weeks 4, 8, and 12</time_frame>
    <description>Percent change in functional C1INH serum levels from pre-infusion to 1 hour post-infusion at Visit 1 and Weeks 4, 8, and 12. Pre-infusion samples obtained at Visit 1 of each therapy period (i.e., baseline) were used to determine change at 1 hour post-infusion for all visits.
Functional C1INH serum levels are expressed as a percent of total detectable C1INH (i.e., functional C1INH/total detectable C1INH).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Total Number of Days of Swelling During Each Prophylactic Therapy Period</measure>
    <time_frame>12 weeks</time_frame>
    <description>A day of swelling was defined as a day that a subject reported swelling at any of the five locations (abdominal, genitourinary, facial, respiratory [including laryngeal], or extremity).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Hereditary Angioedema</condition>
  <arm_group>
    <arm_group_label>C1INH-nf First, then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1,000 Units (U) of C1INH-nf administered intravenously (IV) every 3 to 4 days (approximately twice weekly) for 12 weeks, followed by matching placebo (saline) administered IV every 3 to 4 days for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo First, then C1INH-nf</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Matching placebo (saline) administered IV every 3 to 4 days (approximately twice weekly) for 12 weeks, followed by 1,000 U of C1INH-nf administered IV every 3 to 4 days for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>C1 esterase inhibitor [human] (C1INH-nf)</intervention_name>
    <arm_group_label>C1INH-nf First, then Placebo</arm_group_label>
    <arm_group_label>Placebo First, then C1INH-nf</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (saline)</intervention_name>
    <arm_group_label>C1INH-nf First, then Placebo</arm_group_label>
    <arm_group_label>Placebo First, then C1INH-nf</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented HAE

          -  Normal C1q level

          -  Relatively frequent angioedema attacks (at least 2 per month on average)

        Exclusion Criteria:

          -  Low C1q level

          -  B-cell malignancy

          -  Presence of anti-C1INH autoantibody

          -  History of allergic reaction to C1INH or other blood products

          -  Narcotic addiction

          -  Current participation in any other investigational drug study or within the past 30
             days

          -  Participation in a C1 esterase inhibitor trial, or received blood or a blood product
             in the past 90 days

          -  Pregnancy or lactation

          -  Any clinically significant medical condition, such as renal failure, that in the
             opinion of the investigator would interfere with the subject's ability to participate
             in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce Zuraw, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allergy and Immunology Associates</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093-0732</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Asthma Clinical Research, Inc</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Allergy and Asthma Clinic</name>
      <address>
        <city>Suwanee</city>
        <state>Georgia</state>
        <zip>30024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hawaii Pacific Health Research Institute</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96826</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Welborn Clinic Allergy and Immunology</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lake Charles Memorial Hospital</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Asthma and Allergy</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Libby Clinic</name>
      <address>
        <city>Libby</city>
        <state>Montana</state>
        <zip>59923</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Childrens Hospital Clinical Research</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Clinic of Tulsa</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Asthma and Dermatology Research Center</name>
      <address>
        <city>Lake Oswego</city>
        <state>Oregon</state>
        <zip>97035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AARA Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tyler County Hospital</name>
      <address>
        <city>Woodville</city>
        <state>Texas</state>
        <zip>75979</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital/Cornerstone Healthcare</name>
      <address>
        <city>Parkersburg</city>
        <state>West Virginia</state>
        <zip>26101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2009</study_first_submitted>
  <study_first_submitted_qc>October 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2009</study_first_posted>
  <results_first_submitted>March 17, 2010</results_first_submitted>
  <results_first_submitted_qc>May 3, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 3, 2010</results_first_posted>
  <last_update_submitted>March 19, 2014</last_update_submitted>
  <last_update_submitted_qc>March 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2014</last_update_posted>
  <responsible_party>
    <name_title>Chief Scientific Officer</name_title>
    <organization>ViroPharma</organization>
  </responsible_party>
  <keyword>Hereditary angioedema</keyword>
  <keyword>HAE</keyword>
  <keyword>C1 esterase inhibitor (human)</keyword>
  <keyword>C1INH-nf</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Complement C1s</mesh_term>
    <mesh_term>Complement C1 Inhibitor Protein</mesh_term>
    <mesh_term>Complement C1 Inactivator Proteins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 26 subjects were enrolled in the study (see Detailed Description). One subject received open-label C1 esterase inhibitor (C1INH-nf) but withdrew prior to randomization. Another subject was randomized but withdrew prior to receiving study drug. 24 subjects were randomized and began therapy with blinded study drug in Period 1.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>C1INH-nf First, Then Placebo</title>
          <description>1,000 Units (U) of C1INH-nf administered intravenously (IV) every 3 to 4 days (approximately twice weekly) for 12 weeks, followed by matching placebo (saline) administered IV every 3 to 4 days for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then C1INH-nf</title>
          <description>Matching placebo (saline) administered IV every 3 to 4 days (approximately twice weekly) for 12 weeks, followed by 1,000 U of C1INH-nf administered IV every 3 to 4 days for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>C1INH-nf First, Then Placebo</title>
          <description>1,000 U of C1INH-nf administered IV every 3 to 4 days (approximately twice weekly) for 12 weeks, followed by matching placebo (saline) administered IV every 3 to 4 days for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo First, Then C1INH-nf</title>
          <description>Matching placebo (saline) administered IV every 3 to 4 days (approximately twice weekly) for 12 weeks, followed by 1,000 U of C1INH-nf administered IV every 3 to 4 days for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Open-label C1INH-nf Only</title>
          <description>One subject received open-label C1INH-nf but withdrew prior to randomization.</description>
        </group>
        <group group_id="B4">
          <title>Randomized, Not Treated</title>
          <description>One subject was randomized but withdrew prior to receiving study drug.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="1"/>
            <count group_id="B4" value="1"/>
            <count group_id="B5" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Hereditary Angioedema (HAE) Attacks During Each Prophylactic Therapy Period</title>
        <description>An HAE attack was defined as the subject-reported indication of swelling at any location following a report of no swelling on the previous day. Analyses include observed attack counts and normalized attack counts (i.e., the number of attacks observed during each therapy period, normalized for the number of days the subject participated in that period).</description>
        <time_frame>12 weeks</time_frame>
        <population>The Efficacy Dataset (N=22) consisted of all randomized subjects who completed 12 weeks of therapy in Period 1 and received at least one infusion of study drug in Period 2.</population>
        <group_list>
          <group group_id="O1">
            <title>C1INH-nf</title>
            <description>1,000 U of C1INH-nf administered IV every 3 to 4 days (approximately twice weekly) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo (saline) administered IV every 3 to 4 days (approximately twice weekly) for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hereditary Angioedema (HAE) Attacks During Each Prophylactic Therapy Period</title>
          <description>An HAE attack was defined as the subject-reported indication of swelling at any location following a report of no swelling on the previous day. Analyses include observed attack counts and normalized attack counts (i.e., the number of attacks observed during each therapy period, normalized for the number of days the subject participated in that period).</description>
          <population>The Efficacy Dataset (N=22) consisted of all randomized subjects who completed 12 weeks of therapy in Period 1 and received at least one infusion of study drug in Period 2.</population>
          <units>attacks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Observed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="5.43"/>
                    <measurement group_id="O2" value="12.7" spread="4.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normalized</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="5.54"/>
                    <measurement group_id="O2" value="12.7" spread="4.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Observed number of attacks.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Normalized number of attacks.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subject Withdrawals During Each Prophylactic Therapy Period</title>
        <description>At the end of each therapy period, each subject was assigned a yes/no drop-out status. A drop-out was defined as a subject who did not have a Week 12 visit record.</description>
        <time_frame>12 weeks</time_frame>
        <population>The Safety Dataset (N=24) consisted of all randomized subjects who received at least 1 complete or partial infusion of study drug. 24 subjects began Period 1 (12 C1INH-nf, 12 placebo) and received study drug. 22 subjects crossed over to Period 2 (11 placebo, 11 C1INH-nf) and received study drug. Thus, 23 randomized subjects received each therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>C1INH-nf</title>
            <description>1,000 U of C1INH-nf administered IV every 3 to 4 days (approximately twice weekly) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo (saline) administered IV every 3 to 4 days (approximately twice weekly) for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subject Withdrawals During Each Prophylactic Therapy Period</title>
          <description>At the end of each therapy period, each subject was assigned a yes/no drop-out status. A drop-out was defined as a subject who did not have a Week 12 visit record.</description>
          <population>The Safety Dataset (N=24) consisted of all randomized subjects who received at least 1 complete or partial infusion of study drug. 24 subjects began Period 1 (12 C1INH-nf, 12 placebo) and received study drug. 22 subjects crossed over to Period 2 (11 placebo, 11 C1INH-nf) and received study drug. Thus, 23 randomized subjects received each therapy.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Period 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.999</p_value>
            <p_value_desc>Period 1.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.999</p_value>
            <p_value_desc>Period 2.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Severity of HAE Attacks During Each Prophylactic Therapy Period</title>
        <description>All attacks in each therapy period were assigned a value of 1 (mild), 2 (moderate), or 3 (severe). Attack severity was considered the highest value assigned by the subject to any swelling location during the attack. Average severity was set to 0 if there was no attack in a period.</description>
        <time_frame>12 weeks</time_frame>
        <population>Efficacy Dataset.</population>
        <group_list>
          <group group_id="O1">
            <title>C1INH-nf</title>
            <description>1,000 U of C1INH-nf administered IV every 3 to 4 days (approximately twice weekly) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo (saline) administered IV every 3 to 4 days (approximately twice weekly) for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Severity of HAE Attacks During Each Prophylactic Therapy Period</title>
          <description>All attacks in each therapy period were assigned a value of 1 (mild), 2 (moderate), or 3 (severe). Attack severity was considered the highest value assigned by the subject to any swelling location during the attack. Average severity was set to 0 if there was no attack in a period.</description>
          <population>Efficacy Dataset.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.85"/>
                    <measurement group_id="O2" value="1.9" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0008</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Duration of HAE Attacks During Each Prophylactic Therapy Period</title>
        <description>The duration of an attack was measured from the first report of swelling at any one of the five locations (abdominal, genitourinary, facial, respiratory [including laryngeal], or extremity) until the first subsequent report of &quot;no swelling&quot; at all five locations.</description>
        <time_frame>12 weeks</time_frame>
        <population>Efficacy Dataset.</population>
        <group_list>
          <group group_id="O1">
            <title>C1INH-nf</title>
            <description>1,000 U of C1INH-nf administered IV every 3 to 4 days (approximately twice weekly) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo (saline) administered IV every 3 to 4 days (approximately twice weekly) for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Duration of HAE Attacks During Each Prophylactic Therapy Period</title>
          <description>The duration of an attack was measured from the first report of swelling at any one of the five locations (abdominal, genitourinary, facial, respiratory [including laryngeal], or extremity) until the first subsequent report of &quot;no swelling&quot; at all five locations.</description>
          <population>Efficacy Dataset.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="1.13"/>
                    <measurement group_id="O2" value="3.4" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Open-label C1INH-nf Infusions Required During Each Prophylactic Therapy Period</title>
        <description>The study design allowed for subjects to be treated with open-label C1INH-nf for laryngeal angioedema, if deemed necessary by the investigator, or prior to emergency surgical procedures.</description>
        <time_frame>12 weeks</time_frame>
        <population>Efficacy Dataset.</population>
        <group_list>
          <group group_id="O1">
            <title>C1INH-nf</title>
            <description>1,000 U of C1INH-nf administered IV every 3 to 4 days (approximately twice weekly) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo (saline) administered IV every 3 to 4 days (approximately twice weekly) for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Open-label C1INH-nf Infusions Required During Each Prophylactic Therapy Period</title>
          <description>The study design allowed for subjects to be treated with open-label C1INH-nf for laryngeal angioedema, if deemed necessary by the investigator, or prior to emergency surgical procedures.</description>
          <population>Efficacy Dataset.</population>
          <units>infusions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="8.66"/>
                    <measurement group_id="O2" value="15.4" spread="8.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Total Number of Days of Swelling During Each Prophylactic Therapy Period</title>
        <description>A day of swelling was defined as a day that a subject reported swelling at any of the five locations (abdominal, genitourinary, facial, respiratory [including laryngeal], or extremity).</description>
        <time_frame>12 weeks</time_frame>
        <population>Efficacy Dataset.</population>
        <group_list>
          <group group_id="O1">
            <title>C1INH-nf</title>
            <description>1,000 U of C1INH-nf administered IV every 3 to 4 days (approximately twice weekly) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo (saline) administered IV every 3 to 4 days (approximately twice weekly) for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Days of Swelling During Each Prophylactic Therapy Period</title>
          <description>A day of swelling was defined as a day that a subject reported swelling at any of the five locations (abdominal, genitourinary, facial, respiratory [including laryngeal], or extremity).</description>
          <population>Efficacy Dataset.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" spread="10.73"/>
                    <measurement group_id="O2" value="29.6" spread="16.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antigenic C1 Inhibitor (C1INH) Serum Levels</title>
        <description>Change in antigenic C1INH serum levels from pre-infusion to 1 hour post-infusion at Visit 1 and Weeks 4, 8, and 12. Pre-infusion samples obtained at Visit 1 of each therapy period (i.e., baseline) were used to determine change at 1 hour post-infusion for all visits.</description>
        <time_frame>Pre-infusion to 1 hour post-infusion at Visit 1 and Weeks 4, 8, and 12</time_frame>
        <population>Efficacy Dataset subjects with data at both sampling time points (N=19 C1INH-nf, N=22 placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>C1INH-nf</title>
            <description>1,000 U of C1INH-nf administered IV every 3 to 4 days (approximately twice weekly) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo (saline) administered IV every 3 to 4 days (approximately twice weekly) for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Antigenic C1 Inhibitor (C1INH) Serum Levels</title>
          <description>Change in antigenic C1INH serum levels from pre-infusion to 1 hour post-infusion at Visit 1 and Weeks 4, 8, and 12. Pre-infusion samples obtained at Visit 1 of each therapy period (i.e., baseline) were used to determine change at 1 hour post-infusion for all visits.</description>
          <population>Efficacy Dataset subjects with data at both sampling time points (N=19 C1INH-nf, N=22 placebo).</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 pre-infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" spread="15.08"/>
                    <measurement group_id="O2" value="14.2" spread="14.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 1 change at 1 hour post-infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" spread="3.70"/>
                    <measurement group_id="O2" value="-0.1" spread="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 change at 1 hour post-infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" spread="5.08"/>
                    <measurement group_id="O2" value="0.1" spread="5.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 change at 1 hour post-infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="5.62"/>
                    <measurement group_id="O2" value="-0.3" spread="3.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 change at 1 hour post-infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" spread="5.93"/>
                    <measurement group_id="O2" value="1.1" spread="5.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Visit 1 change at 1 hour post-infusion.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Week 4 change at 1 hour post-infusion.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Week 8 change at 1 hour post-infusion.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0028</p_value>
            <p_value_desc>Week 12 change at 1 hour post-infusion.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional C1INH Serum Levels</title>
        <description>Percent change in functional C1INH serum levels from pre-infusion to 1 hour post-infusion at Visit 1 and Weeks 4, 8, and 12. Pre-infusion samples obtained at Visit 1 of each therapy period (i.e., baseline) were used to determine change at 1 hour post-infusion for all visits.
Functional C1INH serum levels are expressed as a percent of total detectable C1INH (i.e., functional C1INH/total detectable C1INH).</description>
        <time_frame>Pre-infusion to 1 hour post-infusion at Visit 1 and Weeks 4, 8, and 12</time_frame>
        <population>Efficacy Dataset subjects with data at both sampling time points (N=20 C1INH-nf, N=22 placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>C1INH-nf</title>
            <description>1,000 U of C1INH-nf administered IV every 3 to 4 days (approximately twice weekly) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo (saline) administered IV every 3 to 4 days (approximately twice weekly) for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Functional C1INH Serum Levels</title>
          <description>Percent change in functional C1INH serum levels from pre-infusion to 1 hour post-infusion at Visit 1 and Weeks 4, 8, and 12. Pre-infusion samples obtained at Visit 1 of each therapy period (i.e., baseline) were used to determine change at 1 hour post-infusion for all visits.
Functional C1INH serum levels are expressed as a percent of total detectable C1INH (i.e., functional C1INH/total detectable C1INH).</description>
          <population>Efficacy Dataset subjects with data at both sampling time points (N=20 C1INH-nf, N=22 placebo).</population>
          <units>percent of functional C1INH</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 pre-infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.9" spread="17.21"/>
                    <measurement group_id="O2" value="31.7" spread="21.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 1 percent change at 1 hour post-infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.0" spread="18.95"/>
                    <measurement group_id="O2" value="-2.4" spread="9.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 percent change at 1 hour post-infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.6" spread="17.62"/>
                    <measurement group_id="O2" value="5.3" spread="26.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 percent change at 1 hour post-infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.1" spread="19.08"/>
                    <measurement group_id="O2" value="5.4" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 percent change at 1 hour post-infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.9" spread="21.07"/>
                    <measurement group_id="O2" value="0.8" spread="23.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Visit 1 percent change at 1 hour post-infusion.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Week 4 percent change at 1 hour post-infusion.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Week 8 percent change at 1 hour post-infusion.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>Week 12 percent change at 1 hour post-infusion.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 6 months (i.e., 24 weeks) of therapy and 3 months of follow-up. 25 subjects received at least 1 dose of study drug and were analyzed for safety; all 25 were exposed to C1INH-nf and 23 were exposed to placebo (see Detailed Description).</time_frame>
      <desc>Presented are treatment-emergent adverse reactions considered to be related to study drug. There were no serious adverse reactions considered related to study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>C1INH-nf</title>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Clinical Study Agreement. Most restrictive provision - PI will not publish results until after first of: multicenter publication is published or 24 months from study end. Thereafter, PI may publish his results. PI must provide copy of proposed publication to sponsor for pre-review. If sponsor requests, PI must delete sponsor confidential information before publication and/or delay publication for 90 days so sponsor can file for patents or take other action to protect its patent rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Scientific Officer</name_or_title>
      <organization>ViroPharma</organization>
      <phone>610-458-7300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

